Table 3 Primary and secondary efficacy outcomes in 103 participants with severe COVID-19 randomized to treatment with convalescent plasma versus placebo.

From: Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)

Primary outcome

CCP; n (%)

Placebo; n (%)

RR (95% CI)

Clinical improvement by D28

31/47 (66.0)

32/50 (64.0)

1.03 (0.77 to 1.38)

Secondary efficacy outcomes

Discharge from hospital by D28

28/46 (60.9)

31/50 (62.0)

1.21 (0.84 to 1.74)

BOSCI improvement: ≥ 2 by D28

31/47 (66.0)

32/50 (64.0)

1.03 (0.77 to 1.38)

Death by D28

11/52 (21.5)

13/51 (25.5)

0.83 (0.41 to 1.68)

Invasive mechanical ventilation

1/52 (1.9)

3/51 (5.9)

0.33 (0.04 to 3.04)

  1. Six participants were discharged from primary acute care prior to Day 28 but were lost to follow up as they were uncontactable at Day 28. Clinical improvement is a composite of discharge from hospital and/or improvement in BOSCI score by ≥ 2 by Day 28.
Back to article page